|
Conducting Comprehensive Toxicological Assessments
|
Research Initiative
|
FDA
|
NIEHS
|
The purpose of this Agreement is to conduct, at FDA/NCTR, comprehensive toxicological assessments on FDA priority chemicals/agents nominated to the National Toxicology Program. Studies can include range finding sub-chronic and chronic, compound-specific mechanistic studies, and consideration of the use of alternate test systems. This combination of studies is designed to facilitate the interpretation of study results in support of comprehensive quantitative human health risk assessments. The primary goal of this program is to develop a comprehensive scientific data base that can be utilized to reduce the uncertainty in risk assessment/risk benefit analysis for specific chemicals with high FDA impact.
|
|
Congenital Heart Public Health Consortium
|
Resource Development
|
AHRQ, CDC
|
NHLBI
|
The Congenital Heart Public Health Consortium (CHPHC) is a group of organizations uniting resources and efforts in public health activities. The mission of the CHPHC is to prevent congenital heart defects and improve outcomes for affected children and adults. The consortium achieves its mission by providing leadership and a unified voice for public health priorities, expanding opportunities for surveillance and public health research, and informing public policy priorities that benefit public health and affected persons. The CHPHC represents various federal, state, and community organizations, including those representing patient/family, clinical, and research interests. It is pooling expertise and experience and using a public health model to address Congenital Heart Disease (CHD) issues across the lifespan.
|
|
Consensus-Based Entity (CBE) Committee
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, HRSA
|
NLM
|
The Consensus-Based Entity (CBE) Committee is a HHS-wide entity, chaired by ASPE, to provide oversight and input into the execution of ASPE’s legislation-mandated contract with the National Quality Forum (the Consensus-Based Entity) for establishing quality and performance measures. NLM participates as an invited member.
|
|
Consortium for TB Biomarkers (CTB2)
|
Resource Development
|
FDA
|
NIAID
|
The Consortium for TB Biomarkers (CTB2) seeks to establish a robust biorepository of well-documented clinical specimens to support the discovery and qualification of biomarkers of TB drug effect, especially surrogate markers for stable cure vs. relapse, and to facilitate development of rapid, reliable TB diagnostics, including tests for drug-susceptibility that would be practical for use in resource poor settings.
|
|
Contact Lens Safety Campaign
|
Public Education Campaign
|
CDC
|
NEI
|
The NEI helped CDC disseminate contact lens safety information via social media during its spring break campaign in March. Additionally, NEI added CDC resources to its Pinterest page.
|
|
Content Standards Workgroup of the Health Information Technology (HIT) Standards Committee
|
Committee, Work group, Advisory group, or Task Force
|
OS
|
NLM
|
The Content Standards Workgroup of the Health Information Technology (HIT) Standards Committee is part of the Federal Advisory Committee that is charged with making recommendations to ONC on standards, implementation specifications, and certification criteria for the electronic exchange and use of health information.
|
|
Council on Emergency Medical Care
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, HRSA, OS, SAMHSA
|
NIMH, NCATS, NHLBI, NICHD, NIGMS, NINDS, NLM
|
The Council on Emergency Medical Care (CEMC) is a coalition comprised of subject-matter experts and policy makers in emergency medical care from organizations across the Federal Government. This entity contributes to the development, advancement, and coordination of federal strategies, policies, and priorities relating to emergency medical care to improve the nation’s emergency care system.
|
|
Countermeasures Against Chemical Threats (CounterACT) Research Network
|
Research Initiative
|
CDC, FDA, OS
|
NINDS, NEI, NIAID, NIAMS, NICHD, NIEHS, NIGMS, NLM
|
The CounterACT program is a translational research program supporting basic, translational, and clinical research aimed at the discovery and/or identification of better therapeutic medical countermeasures and/or diagnostic technologies against chemical threat agents, and facilitates their movement through the regulatory process in collaboration with other federal departments and agencies, such as the Biomedical Advanced Research and Development Authority (HHS BARDA). The program includes a comprehensive network of Research Centers of Excellence, individual co-operative research projects, small business innovation research grants, contracts, and interagency agreements with the Department of Defense. Among other activities, NINDS organizes an annual meeting of investigators supported by the program allowing researchers to share information, encourage collaboration, and enable NIH staff to evaluate the group’s progress on themes such as nerve agents, seizure detection technology, cyanide, and sulfur mustard.
|
|
Country Work in Cancer Research and Cancer Control Planning Strengthening – Kenya
|
Other
|
CDC
|
NCI, FIC, NIAID
|
Kenya has an estimated population of over 42 million. Cancer ranks third as a cause of death after infectious and cardiovascular diseases. It estimated that over 18,000 Kenyans die of cancer annually. The most common types of cancer in Kenya are cancers of the cervix, breast, esophagus and prostate. The Ministry of Health released a National Cancer Control Strategy (2010-2015) and a National Cervical Cancer Prevention Program Strategic Plan (2012-2015). NCI looks to build upon those efforts in coordination with the many US government and non-governmental partners (NGOs) working in country. US government agencies, including the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Disease (NIAID), the Fogarty International Center (FIC), the Centers for Disease Control (CDC), and the US Agency for International Development (USAID) have a significant presence in Kenya. Between FY2010 and FY2012, there were 121 NIH or CDC awards totaling $160.1M. USAID invested $700 million in Kenya in FY2011. At least 6 NCI-designated cancer centers have activities in Kenya ranging from capacity building for cancer screening and treatment, to studies of cancers associated with chronic infection, including HPV. Notably, Moi University has hosted the Academic Model Providing Access to Healthcare (AMPATH), in partnership with Indiana University (IU), since 2001. The AMPATH-Moi-IU partnership has created the largest clinical research data enterprises in the developing world and includes 18 HIV clinics in western Kenya with 2,000 new patients enrolling per month as of 2012.
|
|
Creutzfeldt-Jakob Disease Surveillance in Recipients of Human Growth Hormone, National Hormone and Pituitary Program (NHPP)
|
Resource Development
|
CDC, FDA
|
NIDDK
|
From 1963 to 1985, the National Hormone and Pituitary Program (NHPP), funded by the U.S. Department of Health and Human Services (HHS), sent Human Growth Hormone (HGH) made from human pituitary glands to hundreds of doctors across the country. As a part of research studies, doctors used the hormone to treat nearly 7,700 children for failure to grow. In 1985, the HHS learned that three people treated with pituitary HGH died of Creutzfeldt-Jakob Disease (CJD), a rare, incurable brain disease. The HHS immediately stopped distributing the hormone and began a national study to learn more about how pituitary HGH treatment may have caused this problem.
|